Loading
The UK gastroenterology society's 2023 guideline for bile duct cancer, written with patient charities; there is no equivalent UK guideline written for gallbladder cancer.
Guideline commissioned by the British Society of Gastroenterology liver section, written by a multidisciplinary committee with patient and public representatives from AMMF (the Cholangiocarcinoma Charity) and PSC Support, with evidence graded in the AGREE II format. The recommendations are framed as guidance rather than protocol. Its scope is cholangiocarcinoma; a Europe PMC search on 24 September 2026 found no UK society guideline specific to gallbladder cancer, so UK gallbladder practice draws on this document, the ESMO guideline and NCCN.
For a UK patient with gallbladder cancer the nearest national guideline is about a neighbouring disease; the UK and NHS page for gallbladder cancer names the gap.
Shares Juan W. Valle, Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
Shares Juan W. Valle, Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
Shares Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
Shares Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
Shares Juan W. Valle, Gallbladder cancer and the tag gallbladder-evidence.
Shares Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
Shares Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
Shares Gallbladder cancer and the tag gallbladder-evidence.